检索

标题
作者
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)
Shisterova O., Golik E.
Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy
Makarenko N.
Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy
Bozhok A., Semiglazov V., Kletsel' A., Arzumanov A., Ivanova O., Semiglazov V.
The role of ESR1 gene mutation in therapy selection for HR+/HER2- metastatic breast cancer: A review
Paichadze A., Chashnikova E., Golubeva S.
Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer
Ognerubov N., Barsukov S.
The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review
Grechukhina K., Kalugin M., Prosvirnov A., Sukhova M., Zhukova L.
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov D., Chulkova S., Shamilov F., Chanturia N., Zheltikov S., Tupitsyn N.
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y., Lyadov V., Poddubnaya I.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I., Frank G., Yagudina R., Koroleva N., Zavalishina L.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G., Safronova O., Khudjakova T., Barabanova L., Punanova N.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.
Bone mineral density in patient with breast cancer
Poddubnaya I., Kizhaev E., Kolyadina I., Banov S., Zhmaeva E., Secko M.
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V., Semiglazov V., Zhil'tsova E.
Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa
Novik A., Ionova T., Kalyadina S.
Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy
Stenina M.
Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode
Arslanov K., Tkachenko G.
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
Samoylenko V., Gorbunova V., Koshelev M., Yurashko K.
Faktory prognoza pri rake molochnoy zhelezy
Bozhok A., Semiglazov V., Semiglazov V., Arzumanov A., Kletsel' A.
Mammography followed by ultrasonography compared to mammography alone for breast cancer screening in women at average risk of breast cancer (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
Editorial B.
Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report
Grechukhina K., Vorontsova K., Filonenko D., Tyutyunnik P., Shchadrova V., Zhukova L.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I., Ganshina I., Kuzmicheva S., Tekeeva A., Kolokolov J., Volkonskii M., Poddubnaya I.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K., Zhukova L.
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
Gorbunova V., Kolyadina I., Kovalenko E., Manziuk L., Artamonova E., Zhukova L., Bolotina L., Semiglazova T., Manikhas A., Raevskaia N., Itkin I., Filonenko D., Zhilyaeva L., Gol'dberg V., Popova N., Ponomarenko D., Shikina V., Suslova I., Romanchuk O., Kozlov D., Rzaev A., Marfutov V., Andreiashkina I., Vladimirova L., Mitashok I., Tikhanovskaia N., Karabina E., Mukhametshina G., Khasanova A., Safina S., Shaidorov M., Morozov D., Prokof'eva E., Kramskaia L., Karandeeva T., Evstigneeva I., Ovchinnikova E., Klement'eva T., Khrupalo O., Tiuvinova E., Sherstnev V., Chernov I., Kolokolov D., Gaisina E., Levchenko N., Chubenko V., Povyshev A., Iudina I., Vorotilina L., Andreeva T., Tumanian G., Koziakov A., Gil'mutdinova L., Osipov M., Shatokhina A., Vazhenina A., Chichkanova A., Vladimirov V., Ivanov A., Belokhvostova A., Cherniakova E., Tul'china E., Maklashova S., Shkodenko O., Kostalanova I., Tarasova A., Kuz'mina E.
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
Pavlikova O., Poddubnaya I., Kolyadina I., Abdullaev A., Komov D., Danzanova T., Sinyukova G., Kozlov N., Ganshina I., Zhukova L., Aliyeva G., Kerimov R., Gordeeva O.
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A., Mosikyan A., Kurilev A., Balykina Y., Proskurin M.
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
Vladimirova L.
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E., Manziuk L.
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A., Ovchinnikova L., Zabelin M., Yakubov T., Sidorov D., Ovchinnikov M.
New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer
Artamonova E., Manzyuk L.
Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy
Artamonova E.
HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy
Ognerubova I.
Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy
Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V., Semiglazov V.
Biologicheskie kharakteristiki opukholi (proliferativnaya aktivnost', ploidnost' i steroidnye retseptory) i ikh vliyanie na neposredstvennye i otdalennye rezul'taty lecheniya zapushchennogo raka molochnoy zhelezy
Nikolaeva T., Vyshinskaya G., Rotobel'skaya L.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K., Sukhova M., Kolyago E., Filonenko D., Zhukova L.
Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Ognerubov N.
Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research
Kolomejtseva A., Bokova S.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D., Kolyadina I., Poddubnaya I., Ganshina I., Khokhlova S., Kоmetova V., Rodionov V.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
Board E.
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Ganshina I., Ivanova K., Lubennikova E., Arkhipov A., Zhukova L.
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
Kovalenko E., Artamonova E., Karabina E., Andreiashkina I., Prokof’eva E., Popova N., Gaisina E., Evstigneeva I., Shaidorov M., Zhiliaeva L., Ponomarenko D., Khasanova A., Mukhametshina G., Koziakov A., Vorotilina L., Povyshev A., Simolina E., Marfutov V., Kozlov D., Suslova I., Shikina V., Karandeeva T., Shepel’ A., Kramskaia L., Oskirko D., Frolova O.
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
Kolyadina I., Bulavina I., Petkau V., Strakhova N., Gorbunova V., Kovalenko E., Manziuk L., Artamonova E., Zhukova L., Bolotina L., Gan'shina I., Semiglazova T., Manikhas A., Raevskaia N., Itkin I., Khokhlova S., Filonenko D., Gol'dberg V., Popova N., Ponomarenko D., Shikina V., Vladimirova L., Tikhanovskaia N., Karabina E., Mukhametshina G., Khasanova A., Safina S., Shaidorov M., Orlov A., Kostalanova I., Levchenko N., Osipov M., Karandeeva T., Evstigneeva I., Chernov I., Kolokolov D., Povyshev A., Shatokhina A., Cherniakova E., Shkodenko O., Kuz'mina E.
The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results)
Stepanova A., Merzlyakova A., Khulamhanova M., Trofimova O.
Dermatomyositis and polymyositis in breast cancer patients: a case reports
Ganshina I., Zhukova L., Burnevitch E., Gordeeva O., Kondratieva O.
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
Savelyeva M., Ignatova A., Panchenko Y., Urvantseva I., Poddubnaya I.
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
Semiglazova T., Klyuge V., Semiglazov V., Teletaeva G., Krivorotko P., Dashyan G., Paltuev R., Tkachenko E., Donskikh R., Semiglazov V.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
Poddubnaya I., Frank G., Yagudina R., Koroleva N., Zavalishina L.
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
Frank G., Ilatovskaia M., Andreeva I., Zavalishina L.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
Press-reliz Na XIII Rossiyskom kongresse onkologov obsudili sostoyanie epidemiologicheskoy programmy skrininga HER2-statusa u zhenshchin, bol'nykh rakom molochnoy zhelezy (RMZh), a takzhe preimushchestvai perspektivy targetnoy terapii preparatami Gertseptin i Avastin
Rol' Taksotera v lechenii metastaticheskogo raka molochnoy zhelezy
Kolyadina I., Makarenko N., Poddubnaya I.
Fulvestrant v sovremennoy terapii rasprostranennogo raka molochnoy zhelezy: farmakoekonomicheskoe obosnovanie
Komarova V., Komarova L., Poddubnaya I.
Sovremennaya taktika ad\"yuvantnoy lekarstvennoy terapii bol'nykh operabel'nym (rannim) rakom molochnoy zhelezy
Perevodchikova N.
Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review
Imyanitov E.
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Shlivko I., Garanina O., Artamonova E., Ganshina I., Zhukova L., Koroleva I., Michenko A., Semiglazova T., Filonenko D.
Synchronous thyroid gland metastases from breast cancer. Case reports
Ognerubov N., Antipova T., Palkina E.
Breast cancer
Zhukova L., Andreeva I., Zavalishina L., Zakiriakhodzhaev A., Koroleva I., Nazarenko A., Paltuev R., Parokonnaia A., Petrovskii A., Portnoi S., Semiglazov V., Semiglazova T., Stenina M., Stepanova A., Trofimova O., Tyulyandin S., Frank G., Frolova M., Shatova I., Nevol’skikh A., Ivanov S., Khailova Z., Gevorkian T.
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Ganshina I., Gordeeva O., Manukian M.
Opportunities for metastatic triple negative breast cancer therapy
Ganshina I., Gordeeva O., Manukyan M.
Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?
Trigolosov A., Uimanov V., Chernikh M., Petrovskiy A., Nikitina E., Nechushkin M.
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
Semiglazova T., Dashyan G., Semiglazov V., Zhabina A., Osipov M., Kotova Z., Klimenko V., Krivorotko P., Semiglazov V.
Male breast cancer: review of the literature
Nikolaev K., Semiglazov V., Semiglazov V.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G., Poddubnaya I., Yagudina R., Borisov D., Koroleva N.
Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii
Zavalishina L., Andreeva Y., Ryazantseva A., Bateva M., Frank G.
Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya
Myasnikova M.
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K., Filonenko D., Sukhova M., Zhukova L.
Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study
Golubenko E., Savelyeva M., Korennaya V., Podzolkova N., Valiev T.
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Chulkova S., Sholokhova E., Poddubnaya I., Stilidi I., Tupitsyn N.
Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence
Editorial B.
Can any breast skin thickening be staged as T4?
Amosova V., Petrovskii A., Karpova M., Ponedel’nikova N., Frolova M.
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Mazurina N., Artamonova E., Beloyartseva M., Volkova E., Ganshina I., Troshina E., Tjulandin S., Chubenko V.
101 - 174 的 174 信息 << < 1 2 

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回(例如,隐含AND)
  • 使用OR结合多个检索词,便于查找含有这些检索词的文章,例如education OR research
  • 使用括号来创建更复杂的查询; 例如:archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如: "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如:online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语